Here's Why Investors Should Consider Buying Corcept Stock Now

Corcept Therapeutics' (CORT) sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome, has been performing well. The drug has been witnessing strong demand in the past couple of quarters. The company is also making good progress with its promising set of pipeline candidates. The successful development and commercialization of its pipeline candidates will be an added boost to the company. Let's dig deeper. Reasons to Invest in CORT Stock Good Rank and Rising Estimates: Cor ...